Mr. Speaker, as a physician, I look at best practices and I look at results. Our neighbour to the south has shown us the way to best practices. The minister has absolutely no excuse for not looking at the kind of legislation that is being put in place by Congress with regard to mandatory early warning systems with a penalty from manufacturers if they are no longer going to be making a drug, so that another manufacturer might want to pick up the drug. That is important.
The minister has a duty to ensure that manufacturing practices for drugs and food in this country are safe for Canadians. She has already said so herself. There are many things the minister can do immediately. But in the long term, there still needs to be a long-term plan to deal with the problem of companies no longer wanting to make drugs because they are not profitable, to deal with the long-term plan for raw materials shortages and to deal with a mandatory reporting site.
I do not know if the hon. member saw it, but there is a press release that just came out from the brand name pharma, research and development pharmaceutical companies, the generic companies, suggesting they are prepared to put $100,000 each into starting a process to deal with this issue. Should the Minister of Health not have done that?